COST-EFFECTIVENESS OF NIVOLUMAB plus IPILIMUMAB IN FIRST-LINE TREATMENT OF ADVANCED OR METASTATIC RENAL CELL CARCINOMA IN THE NETHERLANDS

被引：0
|
作者：
Klijn, S. [1 ]
Van de Wetering, G. [1 ]
Malcolm, B. [2 ]
Dale, P. [2 ]
Pompen, M. [3 ]
Stevanovic, J. [3 ]
机构：
[1] Pharmerit Int, Rotterdam, Netherlands
[2] Bristol Myers Squibb, Uxbridge, Middx, England
[3] Bristol Myers Squibb, Utrecht, Netherlands
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.09.272
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN190
引用
收藏
页码：S46 / S46
页数：1
相关论文
共 50 条
  • [41] COST-EFFECTIVENESS OF NIVOLUMAB PLUS IPILIMUMAB IN ADVANCED MELANOMA
    Tibet, B.
    VALUE IN HEALTH, 2018, 21 : S45 - S45
  • [42] Atezolizumab plus bevacizumab versus nivolumab as first-line treatment for advanced or unresectable hepatocellular carcinoma: A cost-effectiveness analysis
    Li, Yan
    Liang, Xueyan
    Li, Huijuan
    Chen, Xiaoyu
    CANCER, 2022, 128 (22) : 3995 - 4003
  • [43] COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB VERSUS SUNITINIB FOR THE FIRST-LINE TREATMENT OF INTERMEDIATE- TO POOR-RISK ADVANCED RENAL CELL CARCINOMA IN FRANCE
    Branchoux, S.
    Negrier, S.
    de Peretti, C.
    Malcolm, B.
    May, J.
    Marie, L.
    Gaudin, A. F.
    Klijn, S.
    Ignacio, T. J.
    VALUE IN HEALTH, 2019, 22 : S477 - S477
  • [44] First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone for advanced esophageal cancer: a cost-effectiveness analysis
    Cao, Xueqiong
    Cai, Hongfu
    Li, Na
    Zheng, Bin
    Zheng, Zhiwei
    Liu, Maobai
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14
  • [45] Cost-Effectiveness of First-Line Nivolumab Plus Ipilimumab Combination Therapy in Advanced Non-Small-Cell Lung Cancer in Japan
    Xiuting Mo
    Kensuke Moriwaki
    Kosuke Morimoto
    Kojiro Shimozuma
    Clinical Drug Investigation, 2022, 42 : 599 - 609
  • [46] Cost-Effectiveness of Nivolumab Plus Ipilimumab Combined with Two Cycles of Chemotherapy as First-Line Treatment in Advanced Non-Small Cell Lung Cancer
    Peng, Ye
    Zeng, Xiaohui
    Peng, Liubao
    Liu, Qiao
    Yi, Lidan
    Luo, Xia
    Li, Sini
    Wang, Liting
    Qin, Shuxia
    Wan, Xiaomin
    Tan, Chongqing
    ADVANCES IN THERAPY, 2021, 38 (07) : 3962 - 3972
  • [47] Cost-Effectiveness of First-Line Nivolumab Plus Ipilimumab Combination Therapy in Advanced Non-Small-Cell Lung Cancer in Japan
    Mo, Xiuting
    Moriwaki, Kensuke
    Morimoto, Kosuke
    Shimozuma, Kojiro
    CLINICAL DRUG INVESTIGATION, 2022, 42 (07) : 599 - 609
  • [48] Cost-effectiveness of nivolumab plus ipilimumab versus chemotherapy as first-line therapy in advanced non-small cell lung cancer
    Shu, Yamin
    Ding, Yiling
    Li, Feie
    Zhang, Qilin
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2023, 114
  • [49] Cost-Effectiveness of Nivolumab Plus Ipilimumab Combined with Two Cycles of Chemotherapy as First-Line Treatment in Advanced Non-Small Cell Lung Cancer
    Ye Peng
    Xiaohui Zeng
    Liubao Peng
    Qiao Liu
    Lidan Yi
    Xia Luo
    Sini Li
    Liting Wang
    Shuxia Qin
    Xiaomin Wan
    Chongqing Tan
    Advances in Therapy, 2021, 38 : 3962 - 3972
  • [50] Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma
    Tannir, Nizar M.
    Signoretti, Sabina
    Choueiri, Toni K.
    McDermott, David F.
    Motzer, Robert J.
    Flaifel, Abdallah
    Pignon, Jean-Christophe
    Ficial, Miriam
    Frontera, Osvaldo Aren
    George, Saby
    Powles, Thomas
    Donskov, Frede
    Harrison, Michael R.
    Barthelemy, Philippe
    Tykodi, Scott S.
    Kocsis, Judit
    Ravaud, Alain
    Rodriguez-Cid, Jeronimo R.
    Pal, Sumanta K.
    Murad, Andre M.
    Ishii, Yuko
    Saggi, Shruti Shally
    McHenry, M. Brent
    Rini, Brian, I
    CLINICAL CANCER RESEARCH, 2021, 27 (01) : 78 - 86
12345